Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Cash from Financing Activities for 6 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 25.24% to $23.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.0 million, a 8.75% increase, with the full-year FY2025 number at $48.0 million, up 8.75% from a year prior.
  • Cash from Financing Activities was $23.2 million for Q4 2025 at GeneDx Holdings, up from $10.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $499.4 million in Q3 2021 to a low of -$2.4 million in Q2 2021.
  • A 5-year average of $48.5 million and a median of $3.9 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 83011.25% in 2023, then tumbled 105.29% in 2024.
  • GeneDx Holdings' Cash from Financing Activities stood at -$1.0 million in 2021, then skyrocketed by 106.32% to $65000.0 in 2022, then soared by 72366.15% to $47.1 million in 2023, then tumbled by 34.14% to $31.0 million in 2024, then fell by 25.24% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Cash from Financing Activities are $23.2 million (Q4 2025), $10.8 million (Q3 2025), and $346000.0 (Q2 2025).